Based on clinical studies there is an increasing body of evidence that the in vivo metabolism of tamoxifen in postmenopausal early breast cancer depends on CYP2D6, thereby altering tamoxifen response (Brauch et al. 2013a, 2013b; Brauch and Schwab 2013). This evidence concerns the gene CYP2D6 and breast carcinoma.